The Role of RIN3 Gene in Alzheimer's Disease Pathogenesis: a Comprehensive Review.

World Health Organization (WHO) (2023) Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia . Accessed 10/05/2023

Iqbal K, Grundke-Iqbal I (2010) Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement 6:420–424. https://doi.org/10.1016/j.jalz.2010.04.006

doi: 10.1016/j.jalz.2010.04.006 pubmed: 20813343 pmcid: 2946155

Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford FFL (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 354:56–58

Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R et al (2008) Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71:1986–1992. https://doi.org/10.1212/01.wnl.0000336925.79704.9f

doi: 10.1212/01.wnl.0000336925.79704.9f pubmed: 19064880 pmcid: 2676975

McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJ, Holland D et al (2009) Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 73:457–465. https://doi.org/10.1212/WNL.0b013e3181b16431

doi: 10.1212/WNL.0b013e3181b16431 pubmed: 19667321 pmcid: 2727145

Arvanitakis Z, Shah RC, Bennett DA (2019) Diagnosis and management of dementia: review. JAMA 322:1589–1599. https://doi.org/10.1001/jama.2019.4782

doi: 10.1001/jama.2019.4782 pubmed: 31638686 pmcid: 7462122

Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J et al (2011) Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement 7:532–539. https://doi.org/10.1016/j.jalz.2011.05.2410

doi: 10.1016/j.jalz.2011.05.2410 pubmed: 21889116 pmcid: 3299979

NIH National Institute on Aging. What Are the Signs of Alzheimer's Disease? 2022

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. https://doi.org/10.1038/ng.440

Sherva R, Baldwin CT, Inzelberg R, Vardarajan B, Cupples LA, Lunetta K et al (2011) Identification of novel candidate genes for Alzheimer’s disease by autozygosity mapping using genome wide SNP data. J Alzheimer’s Dis 23:349–359. https://doi.org/10.3233/JAD-2010-100714

doi: 10.3233/JAD-2010-100714

Mahley RW, Weisgraber KH, Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res 50(Suppl):S183–S188. https://doi.org/10.1194/jlr.R800069-JLR200

doi: 10.1194/jlr.R800069-JLR200 pubmed: 19106071 pmcid: 2674716

Karch CM, Goate AM (2015) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77:43–51. https://doi.org/10.1016/j.biopsych.2014.05.006

doi: 10.1016/j.biopsych.2014.05.006 pubmed: 24951455

Xu W, Weissmiller AM, White JA, Fang F, Wang X, Wu Y et al (2016) Amyloid precursor protein–mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest 126:1815–1833. https://doi.org/10.1172/JCI82409

doi: 10.1172/JCI82409 pubmed: 27064279 pmcid: 4855914

Nixon RA (2005) Endosome function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases. Neurobiol Aging 26:373–382. https://doi.org/10.1016/j.neurobiolaging.2004.09.018

doi: 10.1016/j.neurobiolaging.2004.09.018 pubmed: 15639316

Shen R, Murphy CJ, Xu X, Hu M, Ding J, Wu C (2022) Ras and Rab Interactor 3: from cellular mechanisms to human diseases. Front Cell Dev Biol 10:824961. https://doi.org/10.3389/fcell.2022.824961

doi: 10.3389/fcell.2022.824961 pubmed: 35359443 pmcid: 8963869

Kajiho H, Sakurai K, Minoda T, Yoshikawa M, Nakagawa S, Fukushima S et al (2011) Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. J Biol Chem 286:24364–24373. https://doi.org/10.1074/jbc.M110.172445

doi: 10.1074/jbc.M110.172445 pubmed: 21586568 pmcid: 3129215

Shen R, Zhao X, He L, Ding Y, Xu W, Lin S et al (2020) Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease. Transl Neurodegener 9:26. https://doi.org/10.1186/s40035-020-00206-1

doi: 10.1186/s40035-020-00206-1 pubmed: 32552912 pmcid: 7301499

(2020) Alzheimer’s disease facts and figures. Alzheimer’s Dement 16:391–460. https://doi.org/10.1002/alz.12068

Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Prim 1:1–18. https://doi.org/10.1038/nrdp.2015.56

doi: 10.1038/nrdp.2015.56

Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet 388:505–517. https://doi.org/10.1016/S0140-6736(15)01124-1

doi: 10.1016/S0140-6736(15)01124-1 pubmed: 26921134

Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L et al (2013) A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the cognitive function and ageing study i and II. Lancet 382:1405–1412. https://doi.org/10.1016/S0140-6736(13)61570-6

doi: 10.1016/S0140-6736(13)61570-6 pubmed: 23871492 pmcid: 3906607

Matthews FE, Stephan BCM, Robinson L, Jagger C, Barnes LE, Arthur A et al (2016) A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun:7. https://doi.org/10.1038/ncomms11398

Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JCL (2018) Alzheimer’s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry 26:347–357. https://doi.org/10.1177/1039856218762308

doi: 10.1177/1039856218762308 pubmed: 29614878

Cannon-Albright LA, Foster NL, Schliep K, Farnham JM, Teerlink CC, Kaddas H et al (2019) Relative risk for Alzheimer disease based on complete family history. Neurology 92:e1745–e1753. https://doi.org/10.1212/WNL.0000000000007231

doi: 10.1212/WNL.0000000000007231 pubmed: 30867271 pmcid: 6511086

Talboom JS, Håberg A, De Both MD, Naymik MA, Schrauwen I, Lewis CR et al (2019) Family history of Alzheimer’s disease alters cognition and is modified by medical and genetic factors. Elife:8. https://doi.org/10.7554/eLife.46179

Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13:788–794. https://doi.org/10.1016/S1474-4422(14)70136-X

doi: 10.1016/S1474-4422(14)70136-X pubmed: 25030513

Ramalho J, Castillo M (2015) Dementia resulting from traumatic brain injury. Dement Neuropsychol 9:356–368. https://doi.org/10.1590/1980-57642015DN94000356

doi: 10.1590/1980-57642015DN94000356 pubmed: 29213985 pmcid: 5619318

Graham NSN, Sharp DJ (2019) Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. J Neurol Neurosurg Psychiatry 90:1221 LP – 1233. https://doi.org/10.1136/jnnp-2017-317557

doi: 10.1136/jnnp-2017-317557

Grant DA, Serpa R, Moattari CR, Brown A, Greco T, Prins ML et al (2018) Repeat mild traumatic brain injury in adolescent rats increases subsequent β-amyloid pathogenesis. J Neurotrauma 35:94–104. https://doi.org/10.1089/neu.2017.5042

doi: 10.1089/neu.2017.5042 pubmed: 28728464 pmcid: 6909680

Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, de Leon MJ et al (2018) Traumatic Brain injury and Alzheimer’s disease: the cerebrovascular link. EBioMedicine 28:21–30. https://doi.org/10.1016/j.ebiom.2018.01.021

doi: 10.1016/j.ebiom.2018.01.021 pubmed: 29396300 pmcid: 5835563

Turner RC, Lucke-Wold BP, Robson MJ, Lee JM, Bailes JE (2016) Alzheimer’s disease and chronic traumatic encephalopathy: distinct but possibly overlapping disease entities. Brain Inj 30:1279–1292. https://doi.org/10.1080/02699052.2016.1193631

doi: 10.1080/02699052.2016.1193631 pubmed: 27715315 pmcid: 5303562

Zhao C, Noble JM, Marder K, Hartman JS, Gu Y, Scarmeas N (2018) Dietary patterns, physical activity, sleep, and risk for dementia and cognitive decline. Curr Nutr Rep 7:335–345. https://doi.org/10.1007/s13668-018-0247-9

doi: 10.1007/s13668-018-0247-9 pubmed: 30413973 pmcid: 6905459

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet (London, England) 396:413–446. https://doi.org/10.1016/S0140-6736(20)30367-6

doi: 10.1016/S0140-6736(20)30367-6 pubmed: 32738937

Mandolesi L, Polverino A, Montuori S, Foti F, Ferraioli G, Sorrentino P et al (2018) Effects of physical exercise on cognitive functioning and wellbeing: biological and psychological benefits. Front Psychol 9:509. https://doi.org/10.3389/fpsyg.2018.00509

doi: 10.3389/fpsyg.2018.00509 pubmed: 29755380 pmcid: 5934999

Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA, Erickson KI et al (2014) Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging 35:S74–S78. https://doi.org/10.1016/j.neurobiolaging.2014.03.033

doi: 10.1016/j.neurobiolaging.2014.03.033 pubmed: 24913896

Stefaniak O, Dobrzyńska M, Drzymała-Czyż S, Przysławski J (2022) Diet in the prevention of Alzheimer’s disease: current knowledge and future research requirements. Nutrients:14. https://doi.org/10.3390/nu14214564

Lee J, Park H, Chey J (2018) Education as a protective factor moderating the effect of depression on memory impairment in elderly women. Psychiatry Investig 15:70–77. https://doi.org/10.4306/pi.2018.15.1.70

doi: 10.4306/pi.2018.15.1.70 pubmed: 29422928 pmcid: 5795034

Baldivia B, Andrade VM, Bueno OFA (2008) Contribution of education, occupation and cognitively stimulating activities to the formation of cognitive reserve. Dement Neuropsychol 2:173–182. https://doi.org/10.1590/S1980-57642009DN20300003

doi: 10.1590/S1980-57642009DN20300003 pubmed: 29213567 pmcid: 5619462

Ma H, Zhou T, Li X, Maraganore D, Heianza Y, Qi L (2022) Early-life educational attainment, APOE ε4 alleles, and incident dementia risk in late life. GeroScience 44:1479–1488. https://doi.org/10.1007/s11357-022-00545-z

doi: 10.1007/s11357-022-00545-z pubmed: 35306636 pmcid: 9213617

Weaver AN, Jaeggi SM (2021) Activity engagement and cognitive performance amongst older adults. Front Psychol 12:620867. https://doi.org/10.3389/fpsyg.2021.620867

doi: 10.3389/fpsyg.2021.620867 pubmed: 33776844 pmcid: 7990770

Cheng S-T (2016) Cognitive reserve and the prevention of dementia: the role of physical and cognitive activities. Curr Psychiatry Rep 18:85. https://doi.org/10.1007/s11920-016-0721-2

doi: 10.1007/s11920-016-0721-2 pubmed: 27481112 pmcid: 4969323

Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333–344. https://doi.org/10.1038/nrn2620

doi: 10.1038/nrn2620 pubmed: 19339974 pmcid: 2908393

Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118. https://doi.org/10.1038/nrneurol.2012.263

doi: 10.1038/nrneurol.2012.263 pubmed: 23296339 pmcid: 3726719

Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20:68–80. https://doi.org/10.1016/S1474-4422(20)30412-9

doi: 10.1016/S1474-4422(20)30412-9 pubmed: 33340485 pmcid: 8096522

Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H et al (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65:650–657. https://doi.org/10.1002/ana.21696

doi: 10.1002/ana.21696 pubmed: 19557866

Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT (2015) APOE ε2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol 77:917–929. https://doi.org/10.1002/ana.24369

doi: 10.1002/ana.24369 pubmed: 25623662 pmcid: 4447539

Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N et al (2019) Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med 25:1680–1683. https://doi.org/10.1038/s41591-019-0611-3

doi: 10.1038/s41591-019-0611-3 pubmed: 31686034 pmcid: 6898984

Bu G (2022) APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants. Mol Neurodegener 17:51. https://doi.org/10.1186/s13024-022-00556-6

doi: 10.1186/s13024-022-00556-6 pubmed: 35922805 pmcid: 9351235

Xia Q, Yang X, Shi J, Liu Z, Peng Y, Wang W et al (2021) The protective A673T mutation of amyloid precursor protein (APP) in Alzheimer’s disease. Mol Neurobiol 58:4038–4050. https://doi.org/10.1007/s12035-021-02385-y

doi: 10.1007/s12035-021-02385-y pubmed: 33914267

Lopera F, Marino C, Chandrahas AS, O’Hare M, Villalba-Moreno ND, Aguillon D et al (2023) Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med 29:1243–1252. https://doi.org/10.1038/s41591-023-02318-3

doi: 10.1038/s41591-023-02318-3 pubmed: 37188781 pmcid: 10202812

Sepulveda-Falla D (2023) Resistant and resilient mutations in protection against familial Alzheimer’s disease: learning from nature. Mol Neurodegener 18:36. https://doi.org/10.1186/s13024-023-00626-3

doi: 10.1186/s13024-023-00626-3 pubmed: 37264439 pmcid: 10236817

Wasser CR, Herz J (2017) Reelin: neurodevelopmental architect and homeostatic regulator of excitatory synapses. J Biol Chem 292:1330–1338. https://doi.org/10.1074/jbc.R116.766782

doi: 10.1074/jbc.R116.766782 pubmed: 27994051

Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C et al (2022) Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. Acta Neuropathol 144:589–601. https://doi.org/10.1007/s00401-022-02467-8

doi: 10.1007/s00401-022-02467-8 pubmed: 35838824 pmcid: 9381462

Ricciarelli R, Fedele E (2017) The amyloid cascade hypothesis in Alzheimer’s disease: it’s time to change our mind. Curr Neuropharmacol 15:926–935. https://doi.org/10.2174/1570159X15666170116143743

doi: 10.2174/1570159X15666170116143743 pubmed: 28093977 pmcid: 5652035

Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344. https://doi.org/10.1056/NEJMra0909142

doi: 10.1056/NEJMra0909142 pubmed: 20107219

Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet:19. https://doi.org/10.1093/hmg/ddq160

Chen JX, Yan SS (2010) Role of mitochondrial amyloid-β in Alzheimer’s disease. J Alzheimer’s Dis:20. https://doi.org/10.3233/JAD-2010-100357

O’Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185–204. https://doi.org/10.1146/annurev-neuro-061010-113613

doi: 10.1146/annurev-neuro-061010-113613 pubmed: 21456963 pmcid: 3174086

Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M (2019) Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 14:5541–5554. https://doi.org/10.2147/IJN.S200490

doi: 10.2147/IJN.S200490 pubmed: 31410002 pmcid: 6650620

Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2:a006270. https://doi.org/10.1101/cshperspect.a006270

doi: 10.1101/cshperspect.a006270 pubmed: 22553493 pmcid: 3331683

Zhao J, Liu X, Xia W, Zhang Y, Wang C (2020) Targeting amyloidogenic processing of APP in Alzheimer’s disease. Front Mol Neurosci 13:137. https://doi.org/10.3389/fnmol.2020.00137

doi: 10.3389/fnmol.2020.00137 pubmed: 32848600 pmcid: 7418514

Soria Lopez JA, González HM, Léger GC (2019) Alzheimer’s disease. In: Handbook of clinical neurology, vol 167. Elsevier B.V., pp. 231–255. https://doi.org/10.1016/B978-0-12-804766-8.00013-3

doi: 10.1016/B978-0-12-804766-8.00013-3

McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866. https://doi.org/10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M

doi: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M pubmed: 10589538

Hyman BT (2011) Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 68:1062–1064. https://doi.org/10.1001/archneurol.2011.70

doi: 10.1001/archneurol.2011.70 pubmed: 21482918

Boros BD, Greathouse KM, Gentry EG, Curtis KA, Birchall EL, Gearing M et al (2017) Dendritic spines provide cognitive resilience against Alzheimer’s disease. Ann Neurol 82:602–614. https://doi.org/10.1002/ana.25049

doi: 10.1002/ana.25049 pubmed: 28921611 pmcid: 5744899

Arenaza-Urquijo EM, Vemuri P (2018) Resistance vs resilience to Alzheimer disease. Neurology 90:695–703. https://doi.org/10.1212/WNL.0000000000005303

doi: 10.1212/WNL.0000000000005303 pubmed: 29592885 pmcid: 5894932

Alfonso S, Kessels HW, Banos CC, Chan TR, Lin ET, Kumaravel G et al (2014) Synapto-depressive effects of amyloid beta require PICK1. Eur J Neurosci 39:1225–1233. https://doi.org/10.1111/ejn.12499

doi: 10.1111/ejn.12499 pubmed: 24713001 pmcid: 3983572

Henley JM, Wilkinson KA (2016) Synaptic AMPA receptor composition in development, plasticity and disease. Nat Rev Neurosci 17:337–350. https://doi.org/10.1038/nrn.2016.37

doi: 10.1038/nrn.2016.37 pubmed: 27080385

Reinders NR, Pao Y, Renner MC, Da Silva-Matos CM, Lodder TR, Malinow R et al (2016) Amyloid-β effects on synapses and memory require AMPA receptor subunit GluA3. Proc Natl Acad Sci USA 113:E6526–E6534. https://doi.org/10.1073/pnas.1614249113

doi: 10.1073/pnas.1614249113 pubmed: 27708157 pmcid: 5081598

Guntupalli S, Jang SE, Zhu T, Huganir RL, Widagdo J, Anggono V (2017) GluA1 subunit ubiquitination mediates amyloid-β-induced loss of surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J Biol Chem 292:8186–8194. https://doi.org/10.1074/jbc.M116.774554

doi: 10.1074/jbc.M116.774554 pubmed: 28377502 pmcid: 5437227

Zhang J, Yin Y, Ji Z, Cai Z, Zhao B, Li J et al (2017) Endophilin2 interacts with GluA1 to mediate AMPA receptor endocytosis induced by oligomeric amyloid-β. Neural Plast 2017. https://doi.org/10.1155/2017/8197085

Müller MK, Jacobi E, Sakimura K, Malinow R, von Engelhardt J (2018) NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid beta (Aβ) overexpressing mice. Acta Neuropathol Commun 6:110. https://doi.org/10.1186/s40478-018-0611-4

doi: 10.1186/s40478-018-0611-4 pubmed: 30352630 pmcid: 6198500

Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM et al (2016) Tau: from research to clinical development. Alzheimer’s Dement 12:1033–1039. https://doi.org/10.1016/j.jalz.2016.03.018

doi: 10.1016/j.jalz.2016.03.018

Dejanovic B, Huntley MA, De Mazière A, Meilandt WJ, Wu T, Srinivasan K et al (2018) Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 100:1322–1336.e7. https://doi.org/10.1016/j.neuron.2018.10.014

doi: 10.1016/j.neuron.2018.10.014 pubmed: 30392797

Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y et al (2018) Tau protein disrupts nucleocytoplasmic transport in Alzheimer’s disease. Neuron 99:925–940.e7. https://doi.org/10.1016/j.neuron.2018.07.039

doi: 10.1016/j.neuron.2018.07.039 pubmed: 30189209 pmcid: 6240334

Braak H, Del Tredici K (2015) The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain 138:2814–2833. https://doi.org/10.1093/brain/awv236

doi: 10.1093/brain/awv236 pubmed: 26283673

Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. https://doi.org/10.1038/gim.2015.117

Lanoiselée H-M, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S et al (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med 14:e1002270. https://doi.org/10.1371/journal.pmed.1002270

doi: 10.1371/journal.pmed.1002270 pubmed: 28350801 pmcid: 5370101

Perkovic MN, Pivac N (n.d.) Genetic markers of Alzheimer’s disease. Springer Singapore. https://doi.org/10.1007/978-981-32-9721-0

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science(80). https://doi.org/10.1126/science.1072994

Zhang C, Browne A, Divito JR, Stevenson JA, Romano D, Dong Y et al (2010) Amyloid-β production via cleavage of amyloid-β protein precursor is modulated by cell density. J Alzheimers Dis 22:683–984. https://doi.org/10.3233/JAD-2010-100816

doi: 10.3233/JAD-2010-100816 pubmed: 20847415 pmcid: 3272776

Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic architecture of Alzheimer’s disease: beyond APP, PSENS and APOE. Neurobiol Aging. https://doi.org/10.1016/j.neurobiolaging.2010.03.025

Kim Y-K (ed) (2019) Frontiers in Psychiatry, vol 1192. Springer Singapore, Singapore. https://doi.org/10.1007/978-981-32-9721-0

doi: 10.1007/978-981-32-9721-0

Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D et al (2013) The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ. Acta Neuropathol Commun 1:60. https://doi.org/10.1186/2051-5960-1-60

doi: 10.1186/2051-5960-1-60 pubmed: 24252272 pmcid: 4226306

Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C et al (2001) The “Arctic” APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat Neurosci. https://doi.org/10.1038/nn0901-887

Rajmohan R, Reddy PH (2017) Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons. J Alzheimers Dis 57:975–999. https://doi.org/10.3233/JAD-160612

doi: 10.3233/JAD-160612 pubmed: 27567878 pmcid: 5793225

Karch CM, Cruchaga C, Goate AM (2014) Alzheimer’s disease genetics: from the bench to the clinic. Neuron. https://doi.org/10.1016/j.neuron.2014.05.041

Lleó A, Waldron E, Von Arnim CAF, Herl L, Tangredi MM, Peltan ID et al (2005) Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for γ-secretase. J Biol Chem. https://doi.org/10.1074/jbc.M413969200

Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V et al (2002) A presenilin-1/γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 21:1948–1956. https://doi.org/10.1093/emboj/21.8.1948

doi: 10.1093/emboj/21.8.1948 pubmed: 11953314 pmcid: 125968

Kopan R, Goate A (2000) A common enzyme connects Notch signaling and Alzheimer’s disease. Genes Dev. https://doi.org/10.1101/gad.836900

De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006304. https://doi.org/10.1101/cshperspect.a006304

doi: 10.1101/cshperspect.a006304 pubmed: 22315713 pmcid: 3253024

Dai MH, Zheng H, Zeng LD, Zhang Y (2018) The genes associated with early-onset Alzheimer’s disease. Oncotarget. https://doi.org/10.18632/oncotarget.23738

Jiao B, Liu X, Zhou L, Wang MH, Zhou Y, Xiao T et al (2015) Polygenic analysis of late-onset Alzheimer’s disease from mainland China. PLoS One. https://doi.org/10.1371/journal.pone.0144898

Allen M, Kachadoorian M, Carrasquillo MM, Karhade A, Manly L, Burgess JD et al (2015) Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurol Genet. https://doi.org/10.1212/NXG.0000000000000012

Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. https://doi.org/10.1038/ng.2802

Larsson M, Duffy DL, Zhu G, Liu JZ, MacGregor S, McRae AF et al (2011) GWAS findings for human iris patterns: associations with variants in genes that influence normal neuronal pattern development. Am J Hum Genet. https://doi.org/10.1016/j.ajhg.2011.07.011

Lai MKP, Tsang SWY, Garcia-Alloza M, Minger SL, Nicoll JAR, Esiri MM et al (2006) Selective effects of the APOE ε4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer’s disease. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2005.12.016

Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. https://doi.org/10.1038/ng0694-180

Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. https://doi.org/10.1212/01.WNL.0000128091.92139.0F

Matukumalli SR, Tangirala R, Rao CM (2017) Clusterin: Full-length protein and one of its chains show opposing effects on cellular lipid accumulation. Sci Rep. https://doi.org/10.1038/srep41235

Li X, Ma Y, Wei X, Li Y, Wu H, Zhuang J et al (2014) Clusterin in Alzheimer’s disease: a player in the biological behavior of amyloid-beta. Neurosci Bull 30:162–168. https://doi.org/10.1007/s12264-013-1391-2

doi: 10.1007/s12264-013-1391-2 pubmed: 24353014

Zlokovic BV (1996) Cerebrovascular transport of Alzheimer’s amyloid β and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. https://doi.org/10.1016/0024-3205(96)00310-4

Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. https://doi.org/10.1038/ng.439

Szymanski M, Wang R, Bassett SS, Avramopoulos D (2011) Alzheimer’s risk variants in the clusterin gene are associated with alternative splicing. Transl Psychiatry. https://doi.org/10.1038/tp.2011.17

Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI et al (2006) The lipoprotein receptor LR11 regulates amyloid β production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. https://doi.org/10.1523/JNEUROSCI.4946-05.2006

Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F et al (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. https://doi.org/10.1038/ng1943

Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M et al (2015) Coding mutations in SORL1 and Alzheimer disease. Ann Neurol. https://doi.org/10.1002/ana.24305

Saito K, Murai J, Kajiho H, Kontani K, Kurosu H, Katada T (2002) A novel binding protein composed of homophilic tetramer exhibits unique properties for the small GTPase Rab5. J Biol Chem 277:3412–3418. https://doi.org/10.1074/jbc.M106276200

doi: 10.1074/jbc.M106276200 pubmed: 11733506

Stenmark H, Vitale G, Ullrich O, Zerial M (1995) Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion. Cell 83:423–432. https://doi.org/10.1016/0092-8674(95)90120-5

doi: 10.1016/0092-8674(95)90120-5 pubmed: 8521472

Gournier H, Stenmark H, Rybin V, Lippé R, Zerial M (1998) Two distinct effectors of the small GTPase Rab5 cooperate in endocytic membrane fusion. EMBO J 17:1930–1940. https://doi.org/10.1093/emboj/17.7.1930

doi: 10.1093/emboj/17.7.1930 pubmed: 9524116 pmcid: 1170539

Bucci C, Parton RG, Mather IH, Stunnenberg H, Simons K, Hoflack B et al (1992) The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 70:715–728. https://doi.org/10.1016/0092-8674(92)90306-W

doi: 10.1016/0092-8674(92)90306-W pubmed: 1516130

Gorvel J-P, Chavrier P, Zerial M, Gruenberg J (1991) rab5 controls early endosome fusion in vitro. Cell 64:915–925. https://doi.org/10.1016/0092-8674(91)90316-Q

doi: 10.1016/0092-8674(91)90316-Q pubmed: 1900457

Ponting CP, Benjamin DR (1996) A novel family of ras-binding domains. Trends Biochem Sci 21:422–425. https://doi.org/10.1016/S0968-0004(96)30038-8

doi: 10.1016/S0968-0004(96)30038-8 pubmed: 8987396

Hofer F, Fields S, Schneider C, Martin GS (1994) Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. Proc Natl Acad Sci 91:11089–11093. https://doi.org/10.1073/pnas.91.23.11089

doi: 10.1073/pnas.91.23.11089 pubmed: 7972015 pmcid: 45172

Kajiho H, Saito K, Tsujita K, Kontani K, Araki Y, Kurosu H et al (2003) RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci 116:4159–4168. https://doi.org/10.1242/jcs.00718

doi: 10.1242/jcs.00718 pubmed: 12972505

Han L, Wong D, Dhaka A, Afar D, White M, Xie W et al (1997) Protein binding and signaling properties of RIN1 suggest a unique effector function. Proc Natl Acad Sci 94:4954–4959. https://doi.org/10.1073/pnas.94.10.4954

doi: 10.1073/pnas.94.10.4954 pubmed: 9144171 pmcid: 24612

Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF (2001) Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell 1:73–82. https://doi.org/10.1016/S1534-5807(01)00008-9

doi: 10.1016/S1534-5807(01)00008-9 pubmed: 11703925

Wigge P, Köhler K, Vallis Y, Doyle CA, Owen D, Hunt SP et al (1997) Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis. Mol Biol Cell 8:2003–2015. https://doi.org/10.1091/mbc.8.10.2003

doi: 10.1091/mbc.8.10.2003 pubmed: 9348539 pmcid: 25662

Wigge P, McMahon HT (1998) The amphiphysin family of proteins and their role in endocytosis at the synapse. Trends Neurosci 21:339–344. https://doi.org/10.1016/S0166-2236(98)01264-8

doi: 10.1016/S0166-2236(98)01264-8 pubmed: 9720601

Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV et al (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry 18:1225–1234. https://doi.org/10.1038/mp.2013.1

doi: 10.1038/mp.2013.1 pubmed: 23399914 pmcid: 3807661

Kunkle BW, Vardarajan BN, Naj AC, Whitehead PL, Rolati S, Slifer S et al (2017) Early-onset Alzheimer disease and candidate risk genes involved in endolysosomal transport. JAMA Neurol 74:1113–1122. https://doi.org/10.1001/jamaneurol.2017.1518

doi: 10.1001/jamaneurol.2017.1518 pubmed: 28738127 pmcid: 5691589

Boden KA, Barber IS, Clement N, Patel T, Guetta-Baranes T, Brookes KJ et al (2017) Methylation profiling RIN3 and MEF2C identifies epigenetic marks associated with sporadic early onset Alzheimer’s disease. J Alzheimer’s Dis Reports 1:97–108. https://doi.org/10.3233/adr-170015

doi: 10.3233/adr-170015

Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3:77sr1–77sr1. https://doi.org/10.1126/scitranslmed.3002369

doi: 10.1126/scitranslmed.3002369 pubmed: 21471435 pmcid: 3130546

Kalin S, Hirschmann DT, Buser DP, Spiess M (2015) Rabaptin5 is recruited to endosomes by Rab4 and Rabex5 to regulate endosome maturation. J Cell Sci 128:4126–4137. https://doi.org/10.1242/jcs.174664

doi: 10.1242/jcs.174664 pubmed: 26430212

Goodman A, Goode BL, Matsudaira P, Fink GR (2003) The Saccharomyces cerevisiae Calponin/Transgelin Homolog Scp1 functions with fimbrin to regulate stability and organization of the actin cytoskeleton. Mol Biol Cell 14:2617–2629. https://doi.org/10.1091/mbc.e03-01-0028

doi: 10.1091/mbc.e03-01-0028 pubmed: 12857851 pmcid: 165663

Nagano M, Toshima JY, Siekhaus DE, Toshima J (2019) Rab5-mediated endosome formation is regulated at the trans-Golgi network. Commun Biol 2:419. https://doi.org/10.1038/s42003-019-0670-5

doi: 10.1038/s42003-019-0670-5 pubmed: 31754649 pmcid: 6858330

Kaur G, Lakkaraju A (2018) Early endosome morphology in health and disease:335–343. https://doi.org/10.1007/978-3-319-75402-4_41

Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB et al (2003) Rab5-stimulated up-regulation of the endocytic pathway increases intracellular β-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Aβ production. J Biol Chem 278:31261–31268. https://doi.org/10.1074/jbc.M304122200

doi: 10.1074/jbc.M304122200 pubmed: 12761223

Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A et al (2003) App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of Down syndrome. J Neurosci 23:6788–6792. https://doi.org/10.1523/JNEUROSCI.23-17-06788.2003

doi: 10.1523/JNEUROSCI.23-17-06788.2003 pubmed: 12890772 pmcid: 6740714

Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M et al (2004) Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome. Neurobiol Aging 25:1263–1272. https://doi.org/10.1016/j.neurobiolaging.2004.02.027

doi: 10.1016/j.neurobiolaging.2004.02.027 pubmed: 15465622

Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447:433–440. https://doi.org/10.1038/nature05919

doi: 10.1038/nature05919 pubmed: 17522677

Labonté B, Suderman M, Maussion G, Navaro L, Yerko V, Mahar I et al (2012) Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry:69. https://doi.org/10.1001/archgenpsychiatry.2011.2287

Maussion G, Yang J, Suderman M, Diallo A, Nagy C, Arnovitz M et al (2014) Functional DNA methylation in a transcript specific 3′UTR region of TrkB associates with suicide. Epigenetics 9:1061–1070. https://doi.org/10.4161/epi.29068

doi: 10.4161/epi.29068 pubmed: 24802768 pmcid: 4164491

Antonell A, Lladó A, Altirriba J, Botta-Orfila T, Balasa M, Fernández M et al (2013) A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer’s disease. Neurobiol Aging 34:1772–1778. https://doi.org/10.1016/j.neurobiolaging.2012.12.026

doi: 10.1016/j.neurobiolaging.2012.12.026 pubmed: 23369545

Juul Rasmussen I, Tybjærg-Hansen A, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R (2019) Blood–brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals. Eur J Epidemiol 34:579–590. https://doi.org/10.1007/s10654-019-00498-2

doi: 10.1007/s10654-019-00498-2 pubmed: 30830563 pmcid: 6497814

Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N et al (2019) Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease. Eur J Hum Genet 27:244–253. https://doi.org/10.1038/s41431-018-0273-5

doi: 10.1038/s41431-018-0273-5 pubmed: 30258121

Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z et al (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512–516. https://doi.org/10.1038/nature11087

doi: 10.1038/nature11087 pubmed: 22622580 pmcid: 4047116

Zhao Z, Sagare AP, Ma Q, Halliday MR, Kong P, Kisler K et al (2015) Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci 18:978–987. https://doi.org/10.1038/nn.4025

doi: 10.1038/nn.4025 pubmed: 26005850 pmcid: 4482781

Yui N, Lu HAJ, Chen Y, Nomura N, Bouley R, Brown D (2013) Basolateral targeting and microtubule-dependent transcytosis of the aquaporin-2 water channel. Am J Physiol Physiol 304:C38–C48. https://doi.org/10.1152/ajpcell.00109.2012

doi: 10.1152/ajpcell.00109.2012

Zeigerer A, Gilleron J, Bogorad RL, Marsico G, Nonaka H, Seifert S et al (2012) Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature 485:465–470. https://doi.org/10.1038/nature11133

doi: 10.1038/nature11133 pubmed: 22622570

Takahashi S, Kubo K, Waguri S, Yabashi A, Shin H-W, Katoh Y et al (2012) Rab11 regulates exocytosis of recycling vesicles at the plasma membrane. J Cell Sci 125:4049–4057. https://doi.org/10.1242/jcs.102913

doi: 10.1242/jcs.102913 pubmed: 22685325

Ahmad S, Bannister C, van der Lee SJ, Vojinovic D, Adams HHH, Ramirez A et al (2018) Disentangling the biological pathways involved in early features of Alzheimer’s disease in the Rotterdam Study. Alzheimer’s Dement 14:848–857. https://doi.org/10.1016/j.jalz.2018.01.005

doi: 10.1016/j.jalz.2018.01.005

Guerreiro R, Brás J, Hardy J (2013) SnapShot: genetics of Alzheimer’s disease. Cell 155:968–968.e1. https://doi.org/10.1016/j.cell.2013.10.037

doi: 10.1016/j.cell.2013.10.037 pubmed: 24209629

Jones L, Lambert J-C, Wang L-S, Choi S-H, Harold D, Vedernikov A et al (2015) Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimer’s Dement 11:658–671. https://doi.org/10.1016/j.jalz.2014.05.1757

doi: 10.1016/j.jalz.2014.05.1757

De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L et al (2014) Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 17:1156–1163. https://doi.org/10.1038/nn.3786

doi: 10.1038/nn.3786 pubmed: 25129075 pmcid: 4292795

Smith AR, Mill J, Smith RG, Lunnon K (2016) Elucidating novel dysfunctional pathways in Alzheimer’s disease by integrating loci identified in genetic and epigenetic studies. Neuroepigenetics 6:32–50. https://doi.org/10.1016/j.nepig.2016.05.001

doi: 10.1016/j.nepig.2016.05.001

Miao M, Yuan F, Ma X, Yang H, Gao X, Zhu Z et al (2021) Methylation of the RIN3 promoter is associated with transient ischemic stroke/mild ischemic stroke with early cognitive impairment. Neuropsychiatr Dis Treat 17:2587–2598. https://doi.org/10.2147/NDT.S320167

doi: 10.2147/NDT.S320167 pubmed: 34408420 pmcid: 8364373

Reitz C (2015) Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities. Expert Rev Mol Diagn 15:339–348. https://doi.org/10.1586/14737159.2015.1002469

doi: 10.1586/14737159.2015.1002469 pubmed: 25634383 pmcid: 4677675

Nishitsuji K, Tomiyama T, Ishibashi K, Ito K, Teraoka R, Lambert MP et al (2009) The E693Δ mutation in amyloid precursor protein increases intracellular accumulation of amyloid β oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 174:957–969. https://doi.org/10.2353/ajpath.2009.080480

doi: 10.2353/ajpath.2009.080480 pubmed: 19164507 pmcid: 2665755

Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K et al (2010) A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30:4845–4856. https://doi.org/10.1523/JNEUROSCI.5825-09.2010

doi: 10.1523/JNEUROSCI.5825-09.2010 pubmed: 20371804 pmcid: 6632783

Nilsson P, Iwata N, Muramatsu S, Tjernberg LO, Winblad B, Saido TC (2010) Gene therapy in Alzheimer’s disease - potential for disease modification. J Cell Mol Med 14:741–757. https://doi.org/10.1111/j.1582-4934.2010.01038.x

doi: 10.1111/j.1582-4934.2010.01038.x pubmed: 20158567 pmcid: 3823109

El-Battari A, Rodriguez L, Chahinian H, Delézay O, Fantini J, Yahi N et al (2021) Gene therapy strategy for Alzheimer’s and Parkinson’s diseases aimed at preventing the formation of neurotoxic oligomers in SH-SY5Y Cells. Int J Mol Sci 22:11550. https://doi.org/10.3390/ijms222111550

doi: 10.3390/ijms222111550 pubmed: 34768981 pmcid: 8583875

Rosenblum WI (2014) Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging 35:969–974. https://doi.org/10.1016/j.neurobiolaging.2013.10.085

doi: 10.1016/j.neurobiolaging.2013.10.085 pubmed: 24210593

Rao CV, Asch AS, Carr DJJ, Yamada HY (2020) “Amyloid-beta accumulation cycle” as a prevention and/or therapy target for Alzheimer’s disease. Aging Cell:19. https://doi.org/10.1111/acel.13109

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL et al (2019) Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med 380:1408–1420. https://doi.org/10.1056/NEJMoa1812840

doi: 10.1056/NEJMoa1812840 pubmed: 30970186 pmcid: 6776078

Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW et al (2020) Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease. JAMA Neurol 77:199. https://doi.org/10.1001/jamaneurol.2019.3988

doi: 10.1001/jamaneurol.2019.3988 pubmed: 31764959

Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312–339. https://doi.org/10.1016/j.cell.2019.09.001

doi: 10.1016/j.cell.2019.09.001 pubmed: 31564456 pmcid: 6778042

Guan P-P, Wang P (2023) The involvement of post-translational modifications in regulating the development and progression of Alzheimer’s disease. Mol Neurobiol 60:3617–3632. https://doi.org/10.1007/s12035-023-03277-z

doi: 10.1007/s12035-023-03277-z pubmed: 36877359

Santos AL, Lindner AB (2017) Protein posttranslational modifications: roles in aging and age-related disease. Oxid Med Cell Longev 2017:1–19. https://doi.org/10.1155/2017/5716409

doi: 10.1155/2017/5716409

Kelley AR, Bach SBH, Perry G (2019) Analysis of post-translational modifications in Alzheimer’s disease by mass spectrometry. Biochim Biophys Acta - Mol Basis Dis 1865:2040–2047. https://doi.org/10.1016/j.bbadis.2018.11.002

doi: 10.1016/j.bbadis.2018.11.002 pubmed: 30481587

Pathak GA, Silzer TK, Sun J, Zhou Z, Daniel AA, Johnson L et al (2019) Genome-wide methylation of mild cognitive impairment in Mexican Americans highlights genes involved in synaptic transport, Alzheimer’s disease-precursor phenotypes, and metabolic morbidities. J Alzheimer’s Dis 72:733–749. https://doi.org/10.3233/JAD-190634

doi: 10.3233/JAD-190634

Feng J, Pang J, He D, Wu Z, Li Q, Ji P et al (2021) Identification of genes with altered methylation and its role in early diagnosis of sepsis-induced acute respiratory distress syndrome. Int J Gen Med 14:243–253. https://doi.org/10.2147/ijgm.s287960

doi: 10.2147/ijgm.s287960 pubmed: 33536775 pmcid: 7847772

Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M, Mulet S et al (2020) Sepsis and coronavirus disease 2019: common features and anti-inflammatory therapeutic approaches. Crit Care Med 48:1841–1844. https://doi.org/10.1097/CCM.0000000000004625

doi: 10.1097/CCM.0000000000004625 pubmed: 32826431

Li H, Liu L, Zhang D, Xu J, Dai H, Tang N et al (2020) SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395:1517–1520. https://doi.org/10.1016/S0140-6736(20)30920-X

doi: 10.1016/S0140-6736(20)30920-X pubmed: 32311318 pmcid: 7164875

Sawalha AH, Zhao M, Coit P, Lu Q (2020) Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol:215. https://doi.org/10.1016/j.clim.2020.108410

Rahman MA, Islam K, Rahman S. Neurobiochemical cross-talk between COVID-19 and Alzheimer’s disease. Mol Neurobiol. 2021;58(3):1017–1023

Steardo L, Steardo L, Zorec R, Verkhratsky A (2020) Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol:229. https://doi.org/10.1111/apha.13473

Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M (2020) Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol 125:481–483. https://doi.org/10.1016/j.anai.2020.07.023

doi: 10.1016/j.anai.2020.07.023 pubmed: 32717301 pmcid: 7380219

Rahman MA, Islam K, Rahman S, Alamin M (2020) Neurobiochemical cross-talk between COVID-19 and Alzheimer’s disease. Mol Neurobiol 58:1017–1023. https://doi.org/10.1007/s12035-020-02177-w

doi: 10.1007/s12035-020-02177-w pubmed: 33078369 pmcid: 7571527

Golde TE, DeKosky ST, Galasko D (2018) Alzheimer’s disease: the right drug, the right time. Science 362:1250–1251. https://doi.org/10.1126/science.aau0437

doi: 10.1126/science.aau0437 pubmed: 30545877

Alteri E, Guizzaro L (2018) Be open about drug failures to speed up research. Nature 563:317–319. https://doi.org/10.1038/d41586-018-07352-7

doi: 10.1038/d41586-018-07352-7 pubmed: 30425369

Watson JL, Ryan L, Silverberg N, Cahan V, Bernard MA (2014) Obstacles and opportunities in Alzheimer’s clinical trial recruitment. Health Aff (Millwood) 33:574–579. https://doi.org/10.1377/hlthaff.2013.1314

doi: 10.1377/hlthaff.2013.1314 pubmed: 24711317

Galvin JE, Meuser TM, Boise L, Connell CM (2009) Predictors of physician referral for patient recruitment to Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord 23:352–356. https://doi.org/10.1097/WAD.0b013e31819e0cac

doi: 10.1097/WAD.0b013e31819e0cac pubmed: 19561438 pmcid: 2787738

Tatulian SA (2022) Challenges and hopes for Alzheimer’s disease. Drug Discov Today 27:1027–1043. https://doi.org/10.1016/j.drudis.2022.01.016

doi: 10.1016/j.drudis.2022.01.016 pubmed: 35121174

Choi SH, Bylykbashi E, Chatila ZK, Lee SW, Pulli B, Clemenson GD et al (2018) Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. Science 80:361. https://doi.org/10.1126/science.aan8821

doi: 10.1126/science.aan8821

The Role of RIN3 Gene in Alzheimer's Disease Pathogenesis: a Comprehensive Review.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Mostafa Meshref (M)

Hazem S Ghaith (HS)

Mohamed Ahmed Hammad (MA)

Mahmoud Mohamed Mohamed Shalaby (MMM)

Faris Ayasra (F)

Fatma Ahmed Monib (FA)

Mohamed S Attia (MS)

Mahmoud A Ebada (MA)

Hanaa Elsayed (H)

Ali Shalash (A)

Eshak I Bahbah (EI)

Classifications MeSH